Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 538

1.

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma.

Armand P, Rodig S, Melnichenko V, Thieblemont C, Bouabdallah K, Tumyan G, Özcan M, Portino S, Fogliatto L, Caballero MD, Walewski J, Gulbas Z, Ribrag V, Christian B, Perini GF, Salles G, Svoboda J, Zain J, Patel S, Chen PH, Ligon AH, Ouyang J, Neuberg D, Redd R, Chatterjee A, Balakumaran A, Orlowski R, Shipp M, Zinzani PL.

J Clin Oncol. 2019 Oct 14:JCO1901389. doi: 10.1200/JCO.19.01389. [Epub ahead of print]

PMID:
31609651
2.

Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma.

Wang M, Rule S, Zinzani PL, Goy A, Casasnovas O, Smith SD, Damaj G, Doorduijn JK, Lamy T, Morschhauser F, Panizo C, Shah B, Davies A, Eek R, Dupuis J, Jacobsen E, Kater AP, Le Gouill S, Oberic L, Robak T, Jain P, Frigault MM, Izumi R, Nguyen D, Patel P, Yin M, Długosz-Danecka M.

Leukemia. 2019 Sep 26. doi: 10.1038/s41375-019-0575-9. [Epub ahead of print] No abstract available.

PMID:
31558766
3.

Successful Employment of Brentuximab Vedotin in a Patient Undergoing Hemodialysis: The First Real-life Experience.

Nanni L, Pellegrini C, Stefoni V, Argnani L, Cavo M, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Aug 30. pii: S2152-2650(19)31251-0. doi: 10.1016/j.clml.2019.07.443. [Epub ahead of print] No abstract available.

PMID:
31543370
4.

Are Biosimilars the Future of Oncology and Haematology?

Zinzani PL, Dreyling M, Gradishar W, Andre M, Esteva FJ, Boulos S, González Barca E, Curigliano G.

Drugs. 2019 Oct;79(15):1609-1624. doi: 10.1007/s40265-019-01193-y.

PMID:
31541401
5.

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2019 Sep 20. pii: mdz386. doi: 10.1093/annonc/mdz386. [Epub ahead of print] No abstract available.

PMID:
31539020
6.

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087.

Chen R, Zinzani PL, Lee HJ, Armand P, Johnson NA, Brice P, Radford J, Ribrag V, Molin D, Vassilakopoulos TP, Tomita A, von Tresckow B, Shipp MA, Lin J, Kim E, Nahar A, Balakumaran A, Moskowitz CH.

Blood. 2019 Oct 3;134(14):1144-1153. doi: 10.1182/blood.2019000324. Epub 2019 Aug 13.

PMID:
31409671
7.

Nivolumab Combined With Brentuximab Vedotin for Relapsed/Refractory Primary Mediastinal Large B-Cell Lymphoma: Efficacy and Safety From the Phase II CheckMate 436 Study.

Zinzani PL, Santoro A, Gritti G, Brice P, Barr PM, Kuruvilla J, Cunningham D, Kline J, Johnson NA, Mehta-Shah N, Manley T, Francis S, Sharma M, Moskowitz AJ.

J Clin Oncol. 2019 Aug 9:JCO1901492. doi: 10.1200/JCO.19.01492. [Epub ahead of print]

PMID:
31398081
8.

BRAF V600E-positive monomorphic epitheliotropic intestinal T-cell lymphoma complicating the course of hairy cell leukemia.

Broccoli A, Bertuzzi C, Fiorentino M, Morigi A, Stefoni V, Agostinelli C, Argnani L, Cavo M, Zinzani PL.

Onco Targets Ther. 2019 Jun 20;12:4807-4812. doi: 10.2147/OTT.S202061. eCollection 2019.

9.

Spontaneous remission of follicular lymphoma.

Morigi A, Casadei B, Argnani L, Cavo M, Zinzani PL.

Hematol Oncol. 2019 Jul 23. doi: 10.1002/hon.2653. [Epub ahead of print]

PMID:
31334854
10.

Role of 18F-FLT PET/CT in suspected recurrent or residual lymphoma: final results of a pilot prospective trial.

Zanoni L, Broccoli A, Lambertini A, Pellegrini C, Stefoni V, Lodi F, Fonti C, Nanni C, Zinzani PL, Fanti S.

Eur J Nucl Med Mol Imaging. 2019 Jul;46(8):1661-1671. doi: 10.1007/s00259-019-04323-6. Epub 2019 May 17.

PMID:
31102000
11.

Integrating precision medicine through evaluation of cell of origin in treatment planning for diffuse large B-cell lymphoma.

Nowakowski GS, Feldman T, Rimsza LM, Westin JR, Witzig TE, Zinzani PL.

Blood Cancer J. 2019 May 16;9(6):48. doi: 10.1038/s41408-019-0208-6. Review.

12.

Lenalidomide Combination Therapy in Relapsed/Refractory Diffuse Large B Cell Lymphoma: The Italian Real-Life Experience.

Marangon M, Stefoni V, Castellino A, Visco C, Tani M, Cox MC, Marasca R, Tecchio C, Devizzi L, Monaco F, Romano A, Rusconi C, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Clin Lymphoma Myeloma Leuk. 2019 Jul;19(7):e321-e323. doi: 10.1016/j.clml.2019.03.020. Epub 2019 Mar 29. No abstract available.

PMID:
31080169
13.

Infection control in patients treated for chronic lymphocytic leukemia with ibrutinib or idelalisib: recommendations from Italian society of hematology.

Zinzani PL, Rambaldi A, Gaidano G, Girmenia C, Marchetti M, Pane F, Tura S, Barosi G.

Leuk Res. 2019 Jun;81:88-94. doi: 10.1016/j.leukres.2019.04.016. Epub 2019 May 2. Review.

PMID:
31055248
14.

Patient-reported outcomes in KEYNOTE-087, a phase 2 study of pembrolizumab in patients with classical Hodgkin lymphoma.

von Tresckow B, Fanale M, Ardeshna KM, Chen R, Meissner J, Morschhauser F, Moskowitz C, Zinzani PL, Giezek H, Balakumaran A, Vo TT, Raut M, Brice P.

Leuk Lymphoma. 2019 Apr 23:1-7. doi: 10.1080/10428194.2019.1602262. [Epub ahead of print]

PMID:
31012356
15.

Consolidation with 90Y ibritumomab tiuxetan radioimmunotherapy in mantle cell lymphoma patients ineligible for high dose therapy: results of the phase II multicentre Polish Lymphoma Research Group trial, after 8-year long follow-up.

Jurczak W, M Gruszka A, Sowa Staszczak A, Dlugosz-Danecka M, Szostek M, Zimowska-Curylo D, Giza A, Krawczyk K, Jakobczyk M, Hubalewska-Dydejczyk A, Szymczyk M, Wróbel T, Knopińska-Posłuszny W, Kisiel E, Skotnicki A, Zinzani PL.

Leuk Lymphoma. 2019 Apr 9:1-8. doi: 10.1080/10428194.2019.1602261. [Epub ahead of print]

PMID:
30961415
16.

Lenalidomide in Pretreated Patients with Diffuse Large B-Cell Lymphoma: An Italian Observational Multicenter Retrospective Study in Daily Clinical Practice.

Broccoli A, Casadei B, Chiappella A, Visco C, Tani M, Cascavilla N, Conconi A, Balzarotti M, Cox MC, Marino D, Goldaniga MC, Marasca R, Tecchio C, Patti C, Musuraca G, Devizzi L, Monaco F, Romano A, Fama A, Zancanella M, Paolini R, Rigacci L, Castellino C, Gaudio F, Argnani L, Zinzani PL.

Oncologist. 2019 Sep;24(9):1246-1252. doi: 10.1634/theoncologist.2018-0603. Epub 2019 Apr 2.

PMID:
30940746
17.

Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS).

Morschhauser F, Flinn IW, Advani R, Sehn LH, Diefenbach C, Kolibaba K, Press OW, Salles G, Tilly H, Chen AI, Assouline S, Cheson BD, Dreyling M, Hagenbeek A, Zinzani PL, Jones S, Cheng J, Lu D, Penuel E, Hirata J, Wenger M, Chu YW, Sharman J.

Lancet Haematol. 2019 May;6(5):e254-e265. doi: 10.1016/S2352-3026(19)30026-2. Epub 2019 Mar 29.

PMID:
30935953
18.

Novel Methods to Improve the Efficiency of Radioimmunotherapy for Non-Hodgkin Lymphoma.

Eskian M, Khorasanizadeh M, Zinzani PL, Illidge TM, Rezaei N.

Int Rev Immunol. 2019;38(2):79-91. doi: 10.1080/08830185.2019.1588266. Epub 2019 Mar 31.

PMID:
30931651
19.

Randomized Phase III Trial of Ibrutinib and Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Non-Germinal Center B-Cell Diffuse Large B-Cell Lymphoma.

Younes A, Sehn LH, Johnson P, Zinzani PL, Hong X, Zhu J, Patti C, Belada D, Samoilova O, Suh C, Leppä S, Rai S, Turgut M, Jurczak W, Cheung MC, Gurion R, Yeh SP, Lopez-Hernandez A, Dührsen U, Thieblemont C, Chiattone CS, Balasubramanian S, Carey J, Liu G, Shreeve SM, Sun S, Zhuang SH, Vermeulen J, Staudt LM, Wilson W; PHOENIX investigators.

J Clin Oncol. 2019 May 20;37(15):1285-1295. doi: 10.1200/JCO.18.02403. Epub 2019 Mar 22.

20.

PD-1 blockade as bridge to allogenic stem cell transplantation in relapsed/refractory Hodgkin lymphoma patients: a retrospective single center case series.

Casadei B, Broccoli A, Stefoni V, Pellegrini C, Marangon M, Morigi A, Nanni L, Lolli G, Carella M, Argnani L, Cavo M, Zinzani PL.

Haematologica. 2019 Mar 19. pii: haematol.2019.215962. doi: 10.3324/haematol.2019.215962. [Epub ahead of print]

21.

Integration of transcriptional and mutational data simplifies the stratification of peripheral T-cell lymphoma.

Maura F, Agnelli L, Leongamornlert D, Bolli N, Chan WC, Dodero A, Carniti C, Heavican TB, Pellegrinelli A, Pruneri G, Butler A, Bhosle SG, Chiappella A, Di Rocco A, Zinzani PL, Zaja F, Piva R, Inghirami G, Wang W, Palomero T, Iqbal J, Neri A, Campbell PJ, Corradini P.

Am J Hematol. 2019 Jun;94(6):628-634. doi: 10.1002/ajh.25450. Epub 2019 Mar 19.

22.

Histological findings in patients with suspected mediastinal lymphoma relapse according to positive positron emission tomography scan during follow-up: a large retrospective analysis in 96 patients.

Broccoli A, Forti Parri SN, Pellegrini C, Casadei B, Bonfanti B, Bertolaccini L, Agostinelli C, Boaron M, Fanti S, Nanni C, Argnani L, Zinzani PL.

Leuk Lymphoma. 2019 Sep;60(9):2247-2254. doi: 10.1080/10428194.2019.1581931. Epub 2019 Mar 1.

PMID:
30821538
23.

DYNAMO: A Phase II Study of Duvelisib (IPI-145) in Patients With Refractory Indolent Non-Hodgkin Lymphoma.

Flinn IW, Miller CB, Ardeshna KM, Tetreault S, Assouline SE, Mayer J, Merli M, Lunin SD, Pettitt AR, Nagy Z, Tournilhac O, Abou-Nassar KE, Crump M, Jacobsen ED, de Vos S, Kelly VM, Shi W, Steelman L, Le N, Weaver DT, Lustgarten S, Wagner-Johnston ND, Zinzani PL.

J Clin Oncol. 2019 Apr 10;37(11):912-922. doi: 10.1200/JCO.18.00915. Epub 2019 Feb 11. Erratum in: J Clin Oncol. 2019 Jun 1;37(16):1448.

PMID:
30742566
24.

Randomized Phase III Study of Alisertib or Investigator's Choice (Selected Single Agent) in Patients With Relapsed or Refractory Peripheral T-Cell Lymphoma.

O'Connor OA, Özcan M, Jacobsen ED, Roncero JM, Trotman J, Demeter J, Masszi T, Pereira J, Ramchandren R, Beaven A, Caballero D, Horwitz SM, Lennard A, Turgut M, Hamerschlak N, d'Amore FA, Foss F, Kim WS, Leonard JP, Zinzani PL, Chiattone CS, Hsi ED, Trümper L, Liu H, Sheldon-Waniga E, Ullmann CD, Venkatakrishnan K, Leonard EJ, Shustov AR; Lumiere Study Investigators.

J Clin Oncol. 2019 Mar 10;37(8):613-623. doi: 10.1200/JCO.18.00899. Epub 2019 Feb 1.

PMID:
30707661
25.

A case report of the long treatment experience of a Sézary syndrome responder patient: 16 years through all the systemic and innovative therapies.

Nanni L, Morigi A, Casadei B, Broccoli A, Stefoni V, Argnani L, Cavo M, Zinzani PL.

Hematol Oncol. 2019 Apr;37(2):202-204. doi: 10.1002/hon.2573. Epub 2019 Jan 30.

PMID:
30637815
26.

Optimal Management of Adverse Events From Copanlisib in the Treatment of Patients With Non-Hodgkin Lymphomas.

Cheson BD, O'Brien S, Ewer MS, Goncalves MD, Farooki A, Lenz G, Yu A, Fisher RI, Zinzani PL, Dreyling M.

Clin Lymphoma Myeloma Leuk. 2019 Mar;19(3):135-141. doi: 10.1016/j.clml.2018.11.021. Epub 2018 Nov 29.

27.

New therapies and old side-effects in mycosis fungoides treatment: brentuximab vedotin-induced alopecia.

Pileri A, Starace M, Alessandrini A, Casadei B, Zinzani PL, Piraccini BM.

Br J Dermatol. 2019 Jun;180(6):1535-1536. doi: 10.1111/bjd.17533. Epub 2019 Feb 5. No abstract available.

PMID:
30561000
28.

Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial.

Horwitz S, O'Connor OA, Pro B, Illidge T, Fanale M, Advani R, Bartlett NL, Christensen JH, Morschhauser F, Domingo-Domenech E, Rossi G, Kim WS, Feldman T, Lennard A, Belada D, Illés Á, Tobinai K, Tsukasaki K, Yeh SP, Shustov A, Hüttmann A, Savage KJ, Yuen S, Iyer S, Zinzani PL, Hua Z, Little M, Rao S, Woolery J, Manley T, Trümper L; ECHELON-2 Study Group.

Lancet. 2019 Jan 19;393(10168):229-240. doi: 10.1016/S0140-6736(18)32984-2. Epub 2018 Dec 4. Erratum in: Lancet. 2019 Jan 19;393(10168):228.

PMID:
30522922
29.

Radioimmunotherapy (RIT) for Follicular Lymphoma achieves long term lymphoma control in first line and at relapse: 8-year follow-up data of 281 patients from the international RIT-registry.

Hohloch K, Windemuth-Kieselbach C, Kolz J, Zinzani PL, Cacchione R, Jurczak W, Bischof Delaloye A, Trümper L, Scholz CW.

Br J Haematol. 2019 Mar;184(6):949-956. doi: 10.1111/bjh.15712. Epub 2018 Dec 4.

PMID:
30515751
30.

The role of transplantation in Hodgkin lymphoma.

Broccoli A, Zinzani PL.

Br J Haematol. 2019 Jan;184(1):93-104. doi: 10.1111/bjh.15639. Epub 2018 Nov 8. Review.

PMID:
30407612
31.

Italian expert panel consensus statement on the optimal use of PD-1 blockade therapy in classical Hodgkin lymphoma.

Zinzani PL, Santoro A, Chiti A, Lastoria S, Pinto A, Rigacci L, Barosi G, Pennisi M, Corradini P.

Leuk Lymphoma. 2019 May;60(5):1204-1213. doi: 10.1080/10428194.2018.1519808. Epub 2018 Oct 15.

PMID:
30322329
32.

Dissection of DLBCL microenvironment provides a gene expression-based predictor of survival applicable to formalin-fixed paraffin-embedded tissue.

Ciavarella S, Vegliante MC, Fabbri M, De Summa S, Melle F, Motta G, De Iuliis V, Opinto G, Enjuanes A, Rega S, Gulino A, Agostinelli C, Scattone A, Tommasi S, Mangia A, Mele F, Simone G, Zito AF, Ingravallo G, Vitolo U, Chiappella A, Tarella C, Gianni AM, Rambaldi A, Zinzani PL, Casadei B, Derenzini E, Loseto G, Pileri A, Tabanelli V, Fiori S, Rivas-Delgado A, López-Guillermo A, Venesio T, Sapino A, Campo E, Tripodo C, Guarini A, Pileri SA.

Ann Oncol. 2018 Dec 1;29(12):2363-2370. doi: 10.1093/annonc/mdy450.

33.

Plaques und Tumoren unter der Therapie mit Mogamulizumab bei einer Patientin mit refraktärem Sézary-Syndrom.

Ricci C, Pileri A, Agostinelli C, Ambrosi F, Zinzani PL, Sabattini E.

J Dtsch Dermatol Ges. 2018 Oct;16(10):1263-1266. doi: 10.1111/ddg.13656_g. No abstract available.

PMID:
30300480
34.

Plaques and tumors in a patient with refractory Sézary syndrome treated with mogamulizumab.

Ricci C, Pileri A, Agostinelli C, Ambrosi F, Zinzani PL, Sabattini E.

J Dtsch Dermatol Ges. 2018 Oct;16(10):1263-1265. doi: 10.1111/ddg.13656. Epub 2018 Oct 1. No abstract available.

PMID:
30277017
35.

The PROCLIPI international registry of early-stage mycosis fungoides identifies substantial diagnostic delay in most patients.

Scarisbrick JJ, Quaglino P, Prince HM, Papadavid E, Hodak E, Bagot M, Servitje O, Berti E, Ortiz-Romero P, Stadler R, Patsatsi A, Knobler R, Guenova E, Child F, Whittaker S, Nikolaou V, Tomasini C, Amitay I, Prag Naveh H, Ram-Wolff C, Battistella M, Alberti-Violetti S, Stranzenbach R, Gargallo V, Muniesa C, Koletsa T, Jonak C, Porkert S, Mitteldorf C, Estrach T, Combalia A, Marschalko M, Csomor J, Szepesi A, Cozzio A, Dummer R, Pimpinelli N, Grandi V, Beylot-Barry M, Pham-Ledard A, Wobser M, Geissinger E, Wehkamp U, Weichenthal M, Cowan R, Parry E, Harris J, Wachsmuth R, Turner D, Bates A, Healy E, Trautinger F, Latzka J, Yoo J, Vydianath B, Amel-Kashipaz R, Marinos L, Oikonomidi A, Stratigos A, Vignon-Pennamen MD, Battistella M, Climent F, Gonzalez-Barca E, Georgiou E, Senetta R, Zinzani P, Vakeva L, Ranki A, Busschots AM, Hauben E, Bervoets A, Woei-A-Jin FJSH, Matin R, Collins G, Weatherhead S, Frew J, Bayne M, Dunnill G, McKay P, Arumainathan A, Azurdia R, Benstead K, Twigger R, Rieger K, Brown R, Sanches JA, Miyashiro D, Akilov O, McCann S, Sahi H, Damasco FM, Querfeld C, Folkes A, Bur C, Klemke CD, Enz P, Pujol R, Quint K, Geskin L, Hong E, Evison F, Vermeer M, Cerroni L, Kempf W, Kim Y, Willemze R.

Br J Dermatol. 2019 Aug;181(2):350-357. doi: 10.1111/bjd.17258. Epub 2018 Nov 25.

PMID:
30267549
36.

The unique biology and treatment of primary mediastinal B-cell lymphoma.

Broccoli A, Zinzani PL.

Best Pract Res Clin Haematol. 2018 Sep;31(3):241-250. doi: 10.1016/j.beha.2018.07.001. Epub 2018 Jul 3. Review.

PMID:
30213393
37.

Management of adverse events associated with idelalisib treatment in chronic lymphocytic leukemia and follicular lymphoma: A multidisciplinary position paper.

Cuneo A, Barosi G, Danesi R, Fagiuoli S, Ghia P, Marzano A, Montillo M, Poletti V, Viale P, Zinzani PL.

Hematol Oncol. 2019 Feb;37(1):3-14. doi: 10.1002/hon.2540. Epub 2018 Sep 5. Review.

38.

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease.

van Rhee F, Voorhees P, Dispenzieri A, Fosså A, Srkalovic G, Ide M, Munshi N, Schey S, Streetly M, Pierson SK, Partridge HL, Mukherjee S, Shilling D, Stone K, Greenway A, Ruth J, Lechowicz MJ, Chandrakasan S, Jayanthan R, Jaffe ES, Leitch H, Pemmaraju N, Chadburn A, Lim MS, Elenitoba-Johnson KS, Krymskaya V, Goodman A, Hoffmann C, Zinzani PL, Ferrero S, Terriou L, Sato Y, Simpson D, Wong R, Rossi JF, Nasta S, Yoshizaki K, Kurzrock R, Uldrick TS, Casper C, Oksenhendler E, Fajgenbaum DC.

Blood. 2018 Nov 15;132(20):2115-2124. doi: 10.1182/blood-2018-07-862334. Epub 2018 Sep 4.

39.

Mogamulizumab versus vorinostat in previously treated cutaneous T-cell lymphoma (MAVORIC): an international, open-label, randomised, controlled phase 3 trial.

Kim YH, Bagot M, Pinter-Brown L, Rook AH, Porcu P, Horwitz SM, Whittaker S, Tokura Y, Vermeer M, Zinzani PL, Sokol L, Morris S, Kim EJ, Ortiz-Romero PL, Eradat H, Scarisbrick J, Tsianakas A, Elmets C, Dalle S, Fisher DC, Halwani A, Poligone B, Greer J, Fierro MT, Khot A, Moskowitz AJ, Musiek A, Shustov A, Pro B, Geskin LJ, Dwyer K, Moriya J, Leoni M, Humphrey JS, Hudgens S, Grebennik DO, Tobinai K, Duvic M; MAVORIC Investigators.

Lancet Oncol. 2018 Sep;19(9):1192-1204. doi: 10.1016/S1470-2045(18)30379-6. Epub 2018 Aug 9. Erratum in: Lancet Oncol. 2018 Nov;19(11):e581.

PMID:
30100375
40.

Siltuximab in relapsed/refractory multicentric Castleman disease: Experience of the Italian NPP program.

Tonialini L, Bonfichi M, Ferrero S, Malipiero G, Nozza A, Argnani L, Zinzani PL.

Hematol Oncol. 2018 Oct;36(4):689-692. doi: 10.1002/hon.2532. Epub 2018 Aug 3.

PMID:
30074630
41.

Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia.

Kreitman RJ, Dearden C, Zinzani PL, Delgado J, Karlin L, Robak T, Gladstone DE, le Coutre P, Dietrich S, Gotic M, Larratt L, Offner F, Schiller G, Swords R, Bacon L, Bocchia M, Bouabdallah K, Breems DA, Cortelezzi A, Dinner S, Doubek M, Gjertsen BT, Gobbi M, Hellmann A, Lepretre S, Maloisel F, Ravandi F, Rousselot P, Rummel M, Siddiqi T, Tadmor T, Troussard X, Yi CA, Saglio G, Roboz GJ, Balic K, Standifer N, He P, Marshall S, Wilson W, Pastan I, Yao NS, Giles F.

Leukemia. 2018 Aug;32(8):1768-1777. doi: 10.1038/s41375-018-0210-1. Epub 2018 Jul 20.

42.

Granulomatous tattoo reaction in a nivolumab-treated patient.

Pileri A, Starace M, Leuzzi M, Agostinelli C, Sabattini E, Morigi A, Zinzani PL, Patrizi A.

G Ital Dermatol Venereol. 2018 Jun 29. doi: 10.23736/S0392-0488.18.06084-4. [Epub ahead of print] No abstract available.

PMID:
29963810
43.

MYC protein expression scoring and its impact on the prognosis of aggressive B-cell lymphoma patients.

Ambrosio MR, Lazzi S, Bello GL, Santi R, Porro LD, de Santi MM, Guazzo R, Mundo L, Rigacci L, Kovalchuck S, Onyango N, Fabbri A, Cencini E, Zinzani PL, Zaja F, Angrilli F, Stelitano C, Cabras MG, Spataro G, Bob R, Menter T, Granai M, Cevenini G, Naresh KN, Stein H, Sabattini E, Leoncini L.

Haematologica. 2019 Jan;104(1):e25-e28. doi: 10.3324/haematol.2018.195958. Epub 2018 Jun 28. No abstract available.

44.

Global patterns of care in advanced stage mycosis fungoides/Sezary syndrome: a multicenter retrospective follow-up study from the Cutaneous Lymphoma International Consortium.

Quaglino P, Maule M, Prince HM, Porcu P, Horwitz S, Duvic M, Talpur R, Vermeer M, Bagot M, Guitart J, Papadavid E, Sanches JA, Hodak E, Sugaya M, Berti E, Ortiz-Romero P, Pimpinelli N, Servitje O, Pileri A, Zinzani PL, Estrach T, Knobler R, Stadler R, Fierro MT, Alberti Violetti S, Amitay-Laish I, Antoniou C, Astrua C, Chaganti S, Child F, Combalia A, Fabbro S, Fava P, Grandi V, Jonak C, Martinez-Escala E, Kheterpal M, Kim EJ, McCormack C, Miyagaki T, Miyashiro D, Morris S, Muniesa C, Nikolaou V, Ognibene G, Onida F, Osella-Abate S, Porkert S, Postigo-Llorente C, Ram-Wolff C, Ribero S, Rogers K, Sanlorenzo M, Stranzenbach R, Spaccarelli N, Stevens A, Zugna D, Rook AH, Geskin LJ, Willemze R, Whittaker S, Hoppe R, Scarisbrick J, Kim Y.

Ann Oncol. 2019 Mar 1;30(3):494. doi: 10.1093/annonc/mdy207. No abstract available.

PMID:
29947731
45.

The Berlin-Frankfurt-Münster protocol for the upfront treatment of aggressive lymphomas: The Bologna experience.

Marangon M, Tonialini L, Morigi A, Stefoni V, Broccoli A, Pellegrini C, Casadei B, Argnani L, Cavo M, Zinzani PL.

Am J Hematol. 2018 Jun 8. doi: 10.1002/ajh.25152. [Epub ahead of print] No abstract available.

46.

A patient with plasmablastic lymphoma achieving long-term complete remission after thalidomide-dexamethasone induction and double autologous stem cell transplantation: a case report.

Broccoli A, Nanni L, Stefoni V, Agostinelli C, Argnani L, Cavo M, Zinzani PL.

BMC Cancer. 2018 Jun 8;18(1):645. doi: 10.1186/s12885-018-4561-9.

47.

Primary cutaneous lymphomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.

Willemze R, Hodak E, Zinzani PL, Specht L, Ladetto M; ESMO Guidelines Committee.

Ann Oncol. 2018 Oct 1;29(Suppl 4):iv30-iv40. doi: 10.1093/annonc/mdy133. No abstract available.

PMID:
29878045
48.

Survival in HIV-infected patients with lymphoma according to the choice of antiretroviral treatment: an observational multicentre study.

Focà E, Cavaglià G, Rusconi S, Cascavilla A, Cenderello G, Re A, Casari S, van den Bogaart L, Zinzani PL, Caracciolo D, Di Perri G, Bonito A, Lucchini A, Cassola G, Viale P, Calcagno A.

HIV Med. 2018 Jun 4. doi: 10.1111/hiv.12624. [Epub ahead of print]

49.

Italian real life experience with ibrutinib: results of a large observational study on 77 relapsed/refractory mantle cell lymphoma.

Broccoli A, Casadei B, Morigi A, Sottotetti F, Gotti M, Spina M, Volpetti S, Ferrero S, Spina F, Pisani F, Merli M, Visco C, Paolini R, Zilioli VR, Baldini L, Di Renzo N, Tosi P, Cascavilla N, Molica S, Ilariucci F, Rigolin GM, D'Alò F, Vanazzi A, Santambrogio E, Marasca R, Mastrullo L, Castellino C, Desabbata G, Scortechini I, Trentin L, Morello L, Argnani L, Zinzani PL.

Oncotarget. 2018 May 4;9(34):23443-23450. doi: 10.18632/oncotarget.25215. eCollection 2018 May 4.

50.

Metabolic heterogeneity on baseline 18FDG-PET/CT scan is a predictor of outcome in primary mediastinal B-cell lymphoma.

Ceriani L, Milan L, Martelli M, Ferreri AJM, Cascione L, Zinzani PL, Di Rocco A, Conconi A, Stathis A, Cavalli F, Bellei M, Cozens K, Porro E, Giovanella L, Johnson PW, Zucca E.

Blood. 2018 Jul 12;132(2):179-186. doi: 10.1182/blood-2018-01-826958. Epub 2018 May 2.

PMID:
29720487

Supplemental Content

Loading ...
Support Center